Genetic Polymorphism in TNF-α Promoter Region: Its Association with Severity and Susceptibility to Rheumatoid Arthritis in Iraqi Patients with Active Disease
DOI:
https://doi.org/10.31351/vol32iss2pp46-57Keywords:
Rheumatoid arthritis, SNPs,, –238 G/A, -1031 T/CAbstract
Objectives: To study the prevalence of rs1799964 (-1031 T/C) and rs361525 (- 238 G/A) SNPs and their effect on the disease activity, severity, and cytokines production in newly diagnosed Iraqi rheumatoid arthritis patients.
Patients and Methods: sixty-three patients were diagnosed by a specialist physician while attending the rheumatology unit and twenty control participated. The inflammatory markers were measured and PCR amplification and sequencing were performed to demonstrate TNF-α SNPs.
Results: Regarding (-1031 C/T) SNP, the TT genotype and allele C were significantly present in the controls, and the CT genotype was distributed significantly in the patients. The TT genotype was mostly distributed in the mild-moderate group, while the CT genotype and allele C were significantly distributed in the severe group. DAS28, TNF-α, IL-1, and ACPA were significantly associated with this SNP. While non-significant differences appeared in the analysis of -238 G/A SNP.
Conclusion: The presence of the CT genotype and C allele of) -1031 C/T( was associated with susceptibility to RA. While the CT genotype and C allele were associated with more severe disease. Also, TT genotype was associated with less severe disease. Furthermore, an association between -1031 C/T and the inflammatory markers and DAS28 was reported.
References
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018; 4: 1–23.
Almoallim H, Al Saleh J, Badsha H, Ahmed HM, Habjoka S, Menassa JA, et al. A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East. Rheumatol Ther. 2021; 8(1): 1–16.
Faiq MK, Kadhim DJ, Gorial FI. Belief about Medicines among a Sample of Iraqi Patients with Rheumatoid Arthritis. Iraqi J Pharm Sci. 2019; 28(2): 134–41.
Simons G, Caplan J, DiSantostefano RL, Veldwijk J, Englbrecht M, Bywall KS, et al. Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations. Arthritis Res Ther. 2022; 24(1) :1–12.
Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA - J Am Med Assoc. 2018; 320(13): 1360–72.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018; 6(1): 15.
Ali ET, Jabbar AS, Mohammed AN. A Comparative Study of Interleukin 6 , Inflammatory Markers , Ferritin , and Hematological Profile in Rheumatoid Arthritis Patients with Anemia of Chronic Disease and Iron Deficiency. Anemia. 2019; 19: 1-7.
Viatte S. Genetics of rheumatoid arthritis susceptibility , severity , and treatment response. Semin Immunopathol. 2017; 39: 395–408.
Terao C, Raychaudhuri S, Gregersen PK. Recent Advances in Defining the Genetic Basis of Rheumatoid Arthritis. Annu Rev Genomics Hum Genet. 2016; 17: 273–301.
Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017; 31(1): 3–18.
Raslan HM, Attia HR, Hamed Ibrahim M, Mahmoud Hassan E, Salama II, Ismail S, et al. Association of anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes with HLA-DRB1 shared epitope alleles in Egyptian rheumatoid arthritis patients. Int J Rheum Dis. 2020; 23(5): 647–53.
Rego-Pérez I, Fernández-Moreno M, Carreira-García V, Blanco FJ. Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Reumatol Clínica (English Ed. 2009; 5(6): 268–79.
Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017; 92: 615–33.
Verweij CL. Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis. Ann Rheum Dis. 1999; 58(1): 20–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
